Cardiogen: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg, synonym AEDR) of the Khavinson family of peptide bioregulators, proposed as a regulator targeted at cardiovascular tissue. Its hypothetical mechanism is epigenetic-transcriptional: short peptides that would modulate gene expression in cardiomyocytes. The evidence is limited and comes almost entirely from a single research group in preclinical models; it is offered exclusively for research use.

Cardiogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (abbreviated AEDR), belonging to the class of "short peptide bioregulators" developed by the group of Vladimir Khavinson and collaborators at the Institute of Bioregulation and Gerontology in St. Petersburg. This class groups a series of di-, tri-, and tetrapeptides designed as synthetic, defined-structure versions of the original peptide extracts obtained from animal organs (the so-called "cytomax"/"cytogen" preparations). Within that logic, each short peptide is nominally associated with a target tissue; Cardiogen is presented as the regulator oriented toward the myocardium and the cardiovascular system. It is important to emphasize from the outset that it is a compound that is poorly characterized in the independent literature: for AEDR no unambiguously assigned CAS number is reported, nor are widely replicated standardized physicochemical data, and most of the published information comes from a single research group. This document is intended for research reference and does not describe an approved therapeutic use.

From a structural standpoint, Cardiogen is a linear peptide of four residues: alanine, glutamic acid, aspartic acid, and arginine. The AEDR sequence is derived directly from its synonyms and is consistent with the design pattern of this family, in which very short peptides (often 2 to 4 amino acids, such as Vilon KE, Epitalon AEDG, or Pinealon EDR) are postulated as active regulatory fragments. The brevity of the chain is central to the group's mechanistic hypothesis: it is argued that peptides of this size can cross membranes and, according to the proposed models, interact with regions of DNA or chromatin. There is, however, no widely available experimental three-dimensional reference structure for AEDR, and its molecular formula and molecular weight are not reported here because no verified value is available; they should not be inferred or invented.

The proposed mechanism of action for Cardiogen is the same conceptual framework that Khavinson has put forward for the entire family of short bioregulators: an epigenetic or "geroprotective" type of action. The central hypothesis holds that these peptides could bind to specific DNA sequences or interact with histones and associated factors, thereby modulating the expression of certain genes and, consequently, protein synthesis in the corresponding tissue—in this case, cardiac tissue. It has been proposed that this could influence cell differentiation processes, the activity of fibroblasts and cardiomyocytes, and markers associated with tissue aging. This model should be treated with caution: although there are publications describing peptide-DNA interactions in silico and in vitro for several members of the family, the extrapolation of those findings to a specific functional effect on the heart in an intact organism has not been independently established. Therefore, the mechanism should be understood as a working hypothesis supported by preliminary evidence, not as a demonstrated and consensus mechanism.

As for documented research applications, Cardiogen appears in the body of work of its group of origin within exploratory studies on tissue regulation and cardiovascular aging in animal models and culture systems. The lines of inquiry reported for this family include: effects on cell proliferation and differentiation in vitro; modulation of senescence markers; and studies of longevity or tissue functionality in animal models of aging. For Cardiogen specifically, the stated interest centers on myocardial tissue and on the hypothesis of functional maintenance of cardiac muscle with age. Nevertheless, the volume of peer-reviewed, controlled literature replicated by independent groups is scarce, and there are no large-scale randomized clinical trials supporting a cardiovascular benefit in humans. Any researcher wishing to work with this compound should design their experiments starting from that limited evidence base and consider rigorous controls.

Regarding the level of evidence, the honest assessment is that Cardiogen falls into the limited-evidence category. The reasons are concrete: (1) the scientific output is heavily concentrated in a single research group; (2) preclinical, in vitro, and in silico data predominate over clinical data; (3) robust independent replications are lacking for the specific peptide AEDR; and (4) it is not consistently physicochemically characterized in public sources. This is not to claim that the compound lacks interest —the hypothesis of short regulatory peptides is legitimate as a research program— but rather to delimit precisely what is known and what is not. Under no circumstances should Cardiogen be presented as a validated cardiological treatment nor should clinical therapeutic efficacy be attributed to it.

In summary, Cardiogen (AEDR / Ala-Glu-Asp-Arg) is a synthetic tetrapeptide from Khavinson's family of peptide bioregulators, proposed as a regulator targeting cardiovascular tissue through a hypothetical epigenetic mechanism. It is a reagent intended for basic and preclinical research, appropriate for groups studying short peptides, peptide-genome interactions, or models of tissue aging, always under controlled laboratory conditions and with a prudent interpretation of the results, given the limited and largely unreplicated nature of the available evidence.